Abbisko turns to IFRS net loss of RMB 193.47 million in FY26 H1; revenue drops 84% to RMB 97.27 million

• Abbisko Cayman posted an IFRS net loss of RMB 193.47 million, swinging from profit; basic loss per share was RMB 0.31.
• Revenue fell 84% to RMB 97.27 million, mainly milestone payments of RMB 92 million and royalties of RMB 1.1 million from Merck.
• IFRS R&D expenses rose 8% to RMB 246.22 million, reflecting pipeline advancement; adjusted IFRS net loss was RMB 141.82 million.
• Cash and bank balances climbed 17% to RMB 2.38 billion, supported by private placement proceeds and licensing revenue.
• Pimicotinib launched in China in March; Merck’s U.S. NDA was accepted in January, while new IND clearances were secured for ABSK211.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260824-12296957), on August 24, 2026, and is solely responsible for the information contained therein.